


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

Claim 1. (currently amended) A 1,2,4-triaminobenzene derivative of formula I



wherein

$R^1$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, acyl, hydroxy- $C_{1-6}$ -alk(en/yn)yl and hydroxy- $C_{3-8}$ -cycloalk(en)yl;

$R^2$  and  $R^{2'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl, aryl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, aryl- $C_{1-6}$ -alk(en/yn)yl, acyl, hydroxy- $C_{1-6}$ -alk(en/yn)yl and hydroxy- $C_{3-8}$ -cycloalk(en)yl;

$R^3$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl, aryl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, aryl- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, aryl- $C_{3-8}$ -cycloalk(en)yl,  $NR^{10}R^{10'}$ - $C_{1-6}$ -alk(en/yn)yl,  $NR^{10}R^{10'}$ - $C_{3-8}$ -cycloalk(en)yl and hydroxy- $C_{3-8}$ -cycloalk(en)yl; wherein

$R^{10}$  and  $R^{10'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, halo- $C_{1-6}$ -alk(en/yn)yl, halo- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl,

cyano-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl and cyano-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, or

R<sup>10</sup> and R<sup>10'</sup> together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms;

X is CO or SO<sub>2</sub>;

Z is O or NR<sup>4</sup>, wherein


R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl; or

R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R<sup>3</sup> and R<sup>4</sup> and the nitrogen atom is optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>-alk(en/yn)yl, aryl and aryl-C<sub>1-6</sub>-alk(en/yn)yl;


q is 0 or 1;

and

Y represents a heteroaryl of formula II or III



II



III

wherein

W is O or S;

**m** is 0, 1, 2 or 3;

**n** is 0, 1, 2, 3 or 4;

**p** is 0 or 1; and

each **R**<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, aryl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)oxy, -CO-NR<sup>6</sup>R<sup>6'</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7'</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup>, SO<sub>2</sub>OR<sup>8</sup>;

wherein

**R**<sup>6</sup> and **R**<sup>6'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and aryl;

**R**<sup>7</sup> and **R**<sup>7'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl and acyl;  
[[and]]

**R**<sup>8</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl and -NR<sup>9</sup>R<sup>9'</sup>; and wherein

**R**<sup>9</sup> and **R**<sup>9'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl;

or pharmaceutically acceptable salts thereof.

Claim 2. (currently amended) [[A]] The compound according to claim 1 wherein **R**<sup>1</sup> is selected from the group consisting of hydrogen and C<sub>1-6</sub>-alk(en/yn)yl.

Claim 3. (currently amended) [[A]] The compound according to ~~any one of claims 1 and 2~~ claim 1 wherein at least one of the substituents **R**<sup>2</sup> and **R**<sup>2'</sup> is a hydrogen atom.

Claim 4. (currently amended) ~~[[A]] The compound according to any one of claims 1-3~~  
claim 1 wherein both  $R^2$  and  $R^{2'}$  are hydrogen atoms.

Claim 5. (currently amended) ~~[[A]] The compound according to any one of claims 1-4~~  
claim 1 wherein  $X$  is CO.

Claim 6. (currently amended) ~~[[A]] The compound according to any one of claims 1-5~~  
claim 1 wherein  $q$  is 0.

Claim 7. (currently amended) ~~[[A]] The compound according to any one of claims 1-5~~  
claim 1 wherein  $q$  is 1 and  $Z$  is an oxygen atom.

Claim 8. (currently amended) ~~[[A]] The compound according to any one of claims 1-7~~  
claim 1 wherein  $R^3$  is selected from the group consisting of  $C_{1-6}$ -alk(en/yn)yl and aryl- $C_{1-6}$ -alk(en/yn)yl.

Claim 9. (currently amended) ~~[[A]] The compound according to claim 8 wherein  $R^3$  is~~  
 $C_{1-6}$ -alk(en/yn)yl.

Claim 10. (currently amended) ~~[[A]] The compound according to claim 8 wherein  $R^3$  is~~  
aryl- $C_{1-6}$ -alk(en/yn)yl.


Claim 11. (currently amended) ~~[[A]] The compound according to any one of claims 1-10~~  
claim 1 wherein  $W$  is an oxygen atom.

Claim 12. (currently amended) ~~[[A]] The compound according to any one of claims 1-11~~  
claim 1 wherein  $W$  is a sulfur atom.


Claim 13. (currently amended) ~~[[A]] The compound according to any one of claims 1-12~~  
claim 1 wherein  $Y$  is of formula II.

Claim 14. (currently amended) ~~[[A]] The compound according to any one of claims 1-12~~  
claim 1 wherein  $Y$  is of formula III.

Claim 15. (currently amended) ~~[[A]] The compound according to any of claims 1-14~~  
claim 1 wherein Y is of formula IIb or IIIb




IIb




IIIb

wherein **W**, **m**, **n**, **p** and  $R^5$  are as defined above.

Claim 16. (currently amended) ~~[[A]] The compound according to any of claims 1-14~~  
claim 1 wherein Y is of formula IIc or IIIc



IIc



IIIc

wherein **W**, **m**, **n**, **p** and  $R^5$  are as defined above.

Claim 17. (currently amended) ~~[[A]] The compound according to any one of claims 1-16~~  
claim 1 wherein each  $R^5$  is independently selected from the group consisting of  $C_{1-6}$ -alk(en/yn)yl, aryl, halogen,  $C_{1-6}$ -alk(en/yn)yloxy,  $-NR^7R^7$ , and  $-SO_2R^8$ .

Claim 18. (currently amended) A compound ~~according to any of claims 1-17, said~~  
~~compound being~~ selected from the group consisting of:

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

(2-Amino-4-[[4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino]-phenyl)-carbamic acid ethyl ester;

{2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-dimethyl-amino-benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

~~{2-Amino-4-[(5-dimethyl-amino-3-methyl-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;~~

{2-Amino-4-[(5-dimethyl-amino-3-methyl-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;

{2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;

N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-2-(4-fluoro-phenyl)-acetamide; and

N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-3,3-dimethyl-butyramide

or a pharmaceutically acceptable salt thereof [[:]] .

Claim 19. (currently amended) A pharmaceutical composition comprising a compound according to ~~any of the claims 1-18~~ claim 1 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.

Claim 20. (currently amended) ~~Use of a compound of any of claims 1-19 for the manufacture of a pharmaceutical preparation~~ A method of treating a subject for the prevention, treatment and/or inhibition of a disorder of the central nervous system comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

Claims 21-25. (cancelled)

Claim 26. (new) The method of claim 20, wherein the disorder of the central nervous system is selected from the group consisting of a seizure disorder, a neuropathic pain disorder, a migraine pain disorder, an anxiety disorder, a neurogenerative disorder and a neuronal hyperexcitation state.

Claim 27. (new) The method of claim 26, wherein the seizure disorder is a convulsion, epilepsy or a status epilepticus.

Claim 28. (new) The method of claim 26, wherein the neuropathic pain disorder is allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy or neuropathic pain related to migraine.

Claim 29. (new) The method of claim 26, wherein the anxiety disorder is anxiety, a generalized anxiety disorder, panic anxiety, an obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, an acute stress reaction, an adjustment disorder, a hypochondriacal disorder, a separation anxiety disorder, agoraphobia, a specific phobia, an anxiety disorder due to a general medical condition or a substance-induced anxiety disorder.

Claim 30. (new) The method of claim 26, wherein the neurodegenerative disorder is Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy, an infection-related encephalopathy, Creutzfeld-Jakob disease, Parkinson's disease or trauma-induced neurodegeneration.

Claim 31. (new) The method of claim 30, wherein the encephalopathy is caused by a rubella virus, a herpes virus or borrelia.

Claim 32. (new) The method of claim 26, wherein the neuronal hyperexcitation state is medicament withdrawal or by intoxication.